Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reuse of single use devices

This article was originally published in The Gray Sheet

Executive Summary

FDA's proposed strategy for regulating reuse of single use medical devices "would continue to ignore the [Food, Drug and Cosmetic Act] and leave patients at risk," the Association of Disposable Device Manufacturers maintains in a Nov. 19 letter to Rep. Fred Upton (R-Mich.). The association expresses support for H.R. 3148, introduced Oct. 26 by Anna Eshoo (D-Calif.) and Upton (1"The Gray Sheet, Nov. 1, p. 6), which "will motivate the FDA to protect U.S. patients from reprocessed single use devices"

You may also be interested in...

House Reprocessed Medical Device Bill May Have Smoother Sailing

Bipartisan support could help facilitate the progress of reprocessed single-use medical device legislation pending in the House during the next congressional session, Hill staffers predict.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts